Galderma, the Dermatology Category Leader, Celebrates the Grand Opening of US Headquarters in Dallas

Galderma has announced the official opening of its US headquarters in downtown Dallas. Galderma's nearly 300 home office employees were relocated to the Trammell Crow Center at 2001 Ross Avenue. On Friday, December 9, Dallas Mayor Eric Johnson, Galderma Chief Executive Officer Flemming Ørnskov, MD, MPH, representatives from the Downtown Dallas Initiative, and Galderma associates attended the grand opening event.

The Trammell Crow Center's cutting-edge office space on the 16th and 17th floors has 50,000 square feet and offers stunning views of downtown and the Dallas Arts District. Its interior is modern and open, intending to encourage collaboration, creativity, productivity, and connections. The new offices include adjustable desks for both standing and sitting, a private nursing room for mothers of newborns, and many lounge areas with soft seating and large meeting spaces for company events and celebrations to promote comfort and well-being.

Galderma is the pure-play dermatology category leader, with a unique dermatology legacy and decades of cutting-edge innovation. Galderma provides a synergistic portfolio of premium flagship brands that span the entire spectrum of the rapidly expanding dermatology market. These brands hold the top market positions in their respective product categories and are distinguished by science-based product differentiation and premium positioning. Galderma's portfolio in dermo-cosmetics includes dermatologist-approved Cetaphil moisturizing and cleansing products for sensitive skin, the physician-dispensed Alastin product line, and Differin, the first FDA-approved prescription-strength retinoid acne treatment available without a doctor's prescription. Its injectable aesthetics portfolio contains various hyaluronic fillers, as well as a biostimulator, and a neuromodulator. Galderma Therapeutic Dermatology products include physician-prescribed, FDA-approved acne, and rosacea treatments.